For the latter therapies, such an approach appears as a new tool for a molecularly targeted treatment against malignant cells, similar to the case of tisotumab vedotin, recently approved for cervical cancer, which could be the forerunner of a new class of anticancer anti-TF agents [15,16]. The gene discussed is TF; the disease is cervical cancer.